September 25, 2026
Drug Digest: Engineering LNPs Beyond the Liver for Genetic Medicines
Acuitas CEO Dr Thomas Madden and NanoVation co-founder and president Dr Dominik Witzigmann discuss how LNP engineering is expanding genetic medicine applications to traditionally undruggable targets.